Seer to Report Second Quarter 2022 Financial Results on August 9, 2022
Rhea-AI Summary
Seer Inc. (NASDAQ: SEER) has scheduled its second quarter 2022 financial results announcement for August 9, 2022, at 1:30 p.m. PT / 4:30 p.m. ET. The event will include a live webcast available on the investor section of its website, with an archived replay posted afterward. Seer is a life sciences company focused on innovative proteomics solutions, specifically through its Proteograph™ Product Suite, which enables efficient and scalable proteomic analysis designed for research purposes.
Positive
- Seer's Proteograph Product Suite offers a new, integrated solution for proteomic analysis.
- The company is scheduled to report its financial results, indicating transparency and communication with investors.
Negative
- None.
News Market Reaction – SEER
In the trading session that priced this news, SEER gained 1.59%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter of 2022 on Tuesday, August 9, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
